Updated clinical data in MDS and AML studies presented this weekend
Reported overall response rate of 45% (5/11) in relapsed AML
Reported overall response rate of 36% (8/22) in HR-MDS
The data continue to support the benefit of bemcentinib in MDS and AML
06 Dec 2020
Promising results in relapsed AML presented at ASH conference
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Promising results in relapsed AML presented at ASH conference
Updated clinical data in MDS and AML studies presented this weekend
Reported overall response rate of 45% (5/11) in relapsed AML
Reported overall response rate of 36% (8/22) in HR-MDS
The data continue to support the benefit of bemcentinib in MDS and AML